A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 651 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR How does processed and red meat cause cancer and how much... March 17, 2021 Doing More—Together—to End Cancer as We Know It February 9, 2023 Lo que debe saber sobre el cáncer de pulmón October 16, 2020 EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients July 26, 2024 Load more HOT NEWS Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ What to Know About Navigating Cancer Care With a Disability: An...
